Klinische studies acute myeloïde leukemie (AML)

Onbehandelde patiënten

ALIDHE (DIM‐95031‐006)

A single arm, open-label Phase 3b study to describe the safety and tolerability of ivosidenib in combination with azacitidine in adult patients newly diagnosed with IDH1m acute myeloid leukemia (AML) ineligible for intensive induction chemotherapy

• Principal investigator: prof. dr. Johan Maertens
• More information: NCT05907057
• Internal reference number: S67409

cAMeLot-2 (75276617AML3001)

A Phase 3 Randomized, Double-blind, Placebo-controlled, Study of Bleximenib, Venetoclax and Azacitidine for the Treatment of Participants with Newly Diagnosed Acute Myeloid Leukemia Harboring KMT2A Rearrangements or NPM1 Mutations who are Ineligible for Intensive Chemotherapy

• Principal investigator: prof. dr. Johan Maertens
• More information: NCT06852222
• Internal reference number: S70109

QuANTUM-Wild (AC220-168)

A Phase 3, Double-Blind, Randomized, Placebo-Controlled Trial of Quizartinib Administered in Combination with Induction and Consolidation Chemotherapy and Administered as Maintenance Therapy in Adult Patients with Newly Diagnosed FLT3-ITD (-) Acute Myeloid Leukemia (QuANTUM-Wild)

• Principal investigator: prof. dr. Johan Maertens
• More information: NCT06578247
• Internal reference number: S69793

HOVON 177 (EVOLVE-2)

Randomized study assessing azacitidine and venetoclax with or without revumenib in adult patients with newly diagnosed NPM1 mutated or KMT2A rearranged AML ineligible for intensive chemotherapy

• Principal investigator: prof. dr. Johan Maertens
• More information: NCT06652438
• Internal reference number: S70299

Behandelde patiënten

DSP-5336-101

A Phase 1/2, Open-Label, Dose-Escalation, Dose-Expansion Study of DSP-5336 in Adult Acute Leukemia Patients with and without Mixed Lineage Leukemia (MLL)-rearrangement or Nucleophosmin 1 (NPM1) Mutation

• Principal investigator: prof. dr. Johan Maertens
• More information: NCT04988555
• Internal reference number: S67836

BYON4413.001

A first-in-human dose escalation and expansion trial with the antibody-drug conjugate BYON4413 to evaluate safety, pharmacokinetics, and preliminary efficacy in patients with relapsed/refractory acute myeloid leukemia or myelodysplastic neoplasms

• Principal investigator: prof. dr. Johan Maertens
• More information: NCT06359002
• Internal reference number: S68489